Bank of America Corp DE Has $19.39 Million Position in Omnicell, Inc. $OMCL

Key Points

• Bank of America increased its Omnicell stake by 31.3% in the first quarter to 580,875 shares valued at approximately $19.39 million. Institutional investors collectively own 97.7% of OMCL.
• Analysts maintain a generally positive outlook, with seven Buy ratings, one Hold and one Sell, producing a consensus “Moderate Buy” rating and $57.86 price target. However, Piper Sandler and KeyCorp recently lowered their targets.
• Omnicell exceeded quarterly expectations, reporting $0.94 in EPS versus the $0.47 consensus and $312.2 million in revenue, up 7.4% year over year. The stock opened at $36.43, below its $39.80 200-day moving average, indicating continued technical weakness.

Bank of America Corp DE raised its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 31.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 580,875 shares of the company's stock after acquiring an additional 138,537 shares during the period. Bank of America Corp DE owned about 1.28% of Omnicell worth $19,390,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in OMCL. AQR Capital Management LLC boosted its stake in shares of Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company's stock worth $627,000 after buying an additional 5,311 shares during the last quarter. Empowered Funds LLC increased its holdings in shares of Omnicell by 14.3% in the first quarter. Empowered Funds LLC now owns 9,953 shares of the company's stock valued at $348,000 after purchasing an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Omnicell by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company's stock valued at $4,337,000 after buying an additional 4,866 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Omnicell by 201.5% during the first quarter. Jane Street Group LLC now owns 163,664 shares of the company's stock worth $5,722,000 after purchasing an additional 109,382 shares during the period. Finally, Creative Planning lifted its holdings in shares of Omnicell by 16.7% during the second quarter. Creative Planning now owns 9,390 shares of the company's stock worth $276,000 after buying an additional 1,347 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Piper Sandler reaffirmed an "overweight" rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. KeyCorp decreased their target price on shares of Omnicell from $70.00 to $65.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. Wall Street Zen upgraded Omnicell from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 10th. Weiss Ratings restated a "hold (c-)" rating on shares of Omnicell in a report on Tuesday, August 4th. Finally, Craig Hallum reissued a "buy" rating and set a $55.00 target price on shares of Omnicell in a research report on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Omnicell currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.86.

Omnicell Stock Performance

NASDAQ:OMCL opened at $36.43 on Thursday. Omnicell, Inc. has a 52-week low of $29.06 and a 52-week high of $55.00. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of 43.37, a PEG ratio of 0.90 and a beta of 0.98. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. The business's fifty day moving average is $40.47 and its 200 day moving average is $39.80.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business had revenue of $312.21 million for the quarter, compared to analysts' expectations of $310.21 million. During the same quarter in the prior year, the firm earned $0.45 earnings per share. The firm's revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Research analysts predict that Omnicell, Inc. will post 1.41 EPS for the current year.

Key Stories Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Zacks raised its FY2026 EPS forecast to $1.49 from $1.27, above the broader consensus estimate of $1.30. It also increased its Q4 2027 estimate to $0.47 from $0.37 and FY2028 estimate to $1.73 from $1.71, suggesting some confidence in longer-term earnings potential. Omnicell analyst estimate report
• Neutral Sentiment: The estimate changes were made by the same research firm that maintains a “Strong Sell” rating on OMCL, limiting the bullish significance of the upgrades. Omnicell’s current-year outlook remains mixed, with forecast FY2026 earnings of $1.49 followed by lower projected FY2027 earnings of $1.27 before recovering to $1.73 in FY2028.
• Negative Sentiment: Zacks cut its Q3 2026 EPS forecast to $0.25 from $0.27 and sharply reduced Q4 2026 EPS to $0.07 from $0.31. These downgrades point to weaker earnings momentum in the second half of 2026 and are likely the most immediate negative factor for the stock.
• Negative Sentiment: Estimates for 2027 were also reduced: Q1 EPS fell to $0.25 from $0.31, Q2 to $0.23 from $0.32, and full-year EPS to $1.27 from $1.34. The Q3 2027 forecast was trimmed slightly to $0.32 from $0.33. Omnicell earnings estimate revisions
• Negative Sentiment: Zacks also lowered its Q1 2028 EPS estimate to $0.40 from $0.41 and reiterated its “Strong Sell” rating. OMCL remains below its 50-day and 200-day moving averages, indicating continued technical weakness despite the recent modest increase in shares.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source